Safety of SGLT-2 inhibitors in patients with glycogen storage disease type Ib and their efficacy in treating disease-associated digestive symptoms and disorders | Synapse
March 3, 2026
Safety of SGLT-2 inhibitors in patients with glycogen storage disease type Ib and their efficacy in treating disease-associated digestive symptoms and disorders
Key Points
SGLT-2 inhibitors show favorable results for alleviating digestive symptoms.
Key evidence indicates significant improvements in metabolic markers after treatment.
Assessment of clinical data highlights the relationship between drug intervention and digestive health.
Findings suggest that SGLT-2 inhibitors may be a valuable option, though further validation is necessary.